465-22-5 Usage
Description
Scillarenin is a bufadienolide derivative, a type of natural compound known for its cardiotonic properties. It is a metabolite of Meproscillarin, which is derived from plants in the genus Scilla. Scillarenin exhibits positive inotropic and chronotropic effects on the heart, making it a potential candidate for the treatment of heart failure and other cardiovascular conditions.
Uses
Used in Pharmaceutical Industry:
Scillarenin is used as a cardiotonic agent for its ability to strengthen the contractions of the heart and increase heart rate. This makes it a potential treatment for heart failure and other cardiovascular conditions where the heart's pumping action is weakened.
Used in Drug Development:
Scillarenin is used in the development of new drugs and therapies for cardiovascular diseases. Its cardiotonic properties are being studied for their potential to improve heart function and treat conditions such as congestive heart failure, arrhythmias, and cardiomyopathies.
Used in Research:
Scillarenin is used as a research tool to study the mechanisms of heart function and the effects of various compounds on cardiac performance. This helps scientists to better understand the underlying causes of heart diseases and develop more effective treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 465-22-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,6 and 5 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 465-22:
(5*4)+(4*6)+(3*5)+(2*2)+(1*2)=65
65 % 10 = 5
So 465-22-5 is a valid CAS Registry Number.
InChI:InChI=1/C24H32O4/c1-22-10-7-17(25)13-16(22)4-5-20-19(22)8-11-23(2)18(9-12-24(20,23)27)15-3-6-21(26)28-14-15/h3,6,13-14,17-20,25,27H,4-5,7-12H2,1-2H3/t17-,18?,19-,20+,22-,23+,24-/m0/s1
465-22-5Relevant articles and documents
-
Stoll et al.
, (1952)
-
Modulators of Hypoxia Inducible Factor-1 and Related Uses
-
Page/Page column 28, (2009/02/11)
The invention features compounds of formulas I or II: and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.
Studies on cardiac ingredients of plants. XI. synthesis of new bufotoxin homologues utilizing scillarenin (the genuine aglycone of proscillaridin), and their biological activities
Tanase,Nagatsu,Murakami,Nagai,Ueda,Sakakibara,Ando,Hotta,Takeya,Asano
, p. 2256 - 2262 (2007/10/02)
New bufotoxin homologues (3) with various lengths of alkyl chain including longer ones thana suberoyl group at C-3 of the steroid nucleus were prepared from proscillaridin (1) via its genuine aglycone, scillarenin (2), in excellent yield. In the course of preparation, we established conditions for efficient enzymatic glycolysis of 1 to give 2 quantitatively. The pharmacological activities of the resulting bufotoxin homologues (3) were evaluated by measurement of the effect on smooth muscle using the mesenteric artery from spontaneously hypertensive rats, inhibitory: effect on Na+, K+-adenosine triphosphatase (ATPase) prepared from dog kidney, and positive inotropic effect (PIE) on isolated guinea-pig papillary muscle preparations; The bufotoxin homologues (3) showed only slight contraction of vascular muscle followed by a small-relaxation,in addition to the high Na+, K+-ATPase inhibitory activity and PIE comparable to those of clinically used ouabain, digoxin, and digitoxin. Those bufotoxin homologues (3) may be useful as cardiac agents with a minimal vascular contractile effect.